PCI Clinical Trial
— BRILIQUEOfficial title:
Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor in Patients Who Have Previously Undergone PCI Procedures and Insertion of Coronary Stents
Verified date | September 2015 |
Source | Örebro University, Sweden |
Contact | n/a |
Is FDA regulated | No |
Health authority | Regional Ethics Committee, Uppsala, Sweden: |
Study type | Observational |
When ticagrelor should be discontinued prior to elective surgery is unclear. The risks of bleeding when it is continued peri-operatively have to be weighed against the risk of coronary artery thrombosis when stopped. This study aims to assess coagulation and thrombocyte function every other day in patients who are taking ticagrelor after coronary artery stents and discontinue therapy at the end of one year.
Status | Completed |
Enrollment | 25 |
Est. completion date | September 2015 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 45 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Patients who are on the Cardiology Clinic's database at the University Hospital, Örebro and shall terminate ticagrelor after one year following PCI and stent placement would be identified and offered to take part in this study. Exclusion Criteria: - Non-responders (not partial responders) to ticagrelor would be excluded from the study. Additionally, patients who are either taking NSAID's regularly or during the last 2 weeks prior to study start would also be excluded as those who have language or cognitive limitations. |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Sweden | University Hospital | Örebro |
Lead Sponsor | Collaborator |
---|---|
Örebro University, Sweden |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Platelet aggregometry | Platelet aggregometry using Multiplate assay would be done prior to termination of ticagrelor treatment and thereafter every other day of 10 days. | 0 - 10 days | No |
Secondary | Thromboelstography | Thromboelastography would be performed prior to termination of ticagrelor treatment and thereafter every other day of 10 days. | 0-10 days | No |
Secondary | Coagulation function tests | Coagulation function would be performed on alternate days starting before termination of ticagrelor. | 0-10 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310046 -
Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial
|
N/A | |
Active, not recruiting |
NCT03058627 -
Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation
|
N/A | |
Completed |
NCT04500912 -
Comparison of the Supraflex Cruz 60 Micron Versus the Ultimaster Tansei 80 Micron in HBR PCI Population
|
N/A | |
Recruiting |
NCT06247982 -
Bail-Out Stenting and Target-vessel Failure After Drug Coated Balloon Coronary percutaneouS Angioplasty for de Novo Lesions
|
||
Active, not recruiting |
NCT03424941 -
The TransCatheter Valve and Vessels Trial
|
N/A | |
Completed |
NCT02849691 -
Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding
|
N/A | |
Completed |
NCT03479840 -
Age-Dependent Impact of the SYNTAX-score on Mortality
|
||
Completed |
NCT03023020 -
Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
|
N/A |